Amarin Corporation plc (ADR) (AMRN), AstraZeneca plc (ADR) (AZN): Right Drug Class, Wrong Company

Page 2 of 2

Now that AstraZeneca plc (ADR) (NYSE:AZN) is out of the picture, Merck & Co., Inc. (NYSE:MRK) seems like the most obvious choice as a partner. The pharma sells Zetia, which lowers cholesterol, so there are the same synergies that AstraZeneca plc (ADR) (NYSE:AZN) will see with Epanova. Merck & Co., Inc. (NYSE:MRK) might even be interested in developing a combination product containing Vascepa and a statin like it has done with Zetia to make Vytorin and Liptruzet.

The article Right Drug Class, Wrong Company originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2